VolitionRx unveils promising proof-of-concept data for leukemia and lymphoma tests
VolitionRx Limited (NYSEAMERICAN:VNRX) said Tuesday that results from its latest proof of concept study show that a single pre-clinical Nu.Q cancer-test assay boasts an impressive ability to detect with accuracy non-Hodgkins lymphoma (NHL) and other types of leukemia.
Using a microtiter plate platform, one pre-clinical Nu.Q. assay – VolitionRxs flagship cancer detection test – detected 80% of newly-diagnosed non-Hodgkins lymphoma and a mix of leukemia cases (including acute lymphocytic leukemia and acute myeloid leukemia) at 95%. The area under the curve (AUC) for this single assay was 91%, the company said.
“This is a very exciting outcome as we continue the development of our assays beyond colorectal, lung and prostate cancer,” said Dr. Jake Micallef, chief scientific officer with VolitionRx. “We have previously announced results from both single assay and panels of Nu.Q biomarkers but the results of this discovery study are the best single Nu.Q. assay result in any cancer we have demonstrated to date.”
As part of the study, blood plasma samples were taken from 62 healthy volunteers with a mean age of 45, as well as 300 patients previously diagnosed with bladder, bone, brain, esophageal, melanoma, skin, uterine and cervical cancers with a mean age of 56; 54 subjects diagnosed with hematopoietic stem cell cancers with a mean age of 57 also participated.
Looking ahead, VolitionRx hopes to evaluate its latest findings in larger clinical trials of “symptomatic” populations.
“There are over 700,000 new cases of NHL, ALL andRead More – Source